2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Pathogenesis, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Immunology, Immunodeficiency, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4404 Innovation requires access: Association between Medicaid expansion and survival in mantle cell lymphoma

Eleftheria Atalla, MD, Qianqian Liu, PhD2, Joel Michalek, PhD3, Marialejandra Torres Viera, MD4, Adolfo Diaz Duque, MD, MSc5
1 UT Health Science Center San Antonio, San Antonio, Texas, United States
2 UT Health Science Center San Antonio, San Antonio, Texas, United States
3 UT Health Science Center San Antonio, San Antonio, Texas, United States
4 Universidad Central de Venezuela, Caracas, Caracas, Venezuela
5 UT Health Science Center San Antonio, San Antonio, Texas, United States

Background

The Affordable Care Act (ACA) Medicaid expansion, implemented in 2014, substantially increased health insurance coverage among low-income populations and has been associated with earlier cancer diagnosis, improved access to timely treatment, and better survival across several cancer types including lung, colon, pancreatic, and breast cancers. Whether these benefits extend to mantle cell lymphoma (MCL) remains unclear. In this study we evaluated whether Medicaid expansion was independently associated with overall survival (OS) among patients with MCL.

Methods

Adult patients diagnosed with MCL between 2004 and 2023 were identified from the National Cancer Database (NCDB). States were categorized according to Medicaid expansion status, and patients were stratified into pre-expansion (2004–2013) and post-expansion (2014–2023) cohorts. Baseline demographic, socioeconomic, and clinical characteristics were compared between groups. OS was estimated using the Kaplan-Meier method with log-rank testing. Difference-in-differences (DiD) analysis was performed to determine whether Medicaid expansion was independently associated with changes in survival beyond nationwide temporal improvements in MCL management.

Results

A total of 42,952 patients with MCL were identified, including 17,666 (41%) diagnosed before Medicaid expansion and 25,286 (59%) after Medicaid expansion. Overall, 32,657 (76%) patients resided in Medicaid expansion states and 10,295 (24%) in non-expansion states. The distribution of patients between expansion and non-expansion states remained similar before (77% vs. 23%) and after (75% vs. 25%) ACA implementation (P<0.001).

Median age increased from 68 to 69 years following ACA implementation (P<0.001). The proportion of male patients remained unchanged (71%) in both eras. Hispanic patients increased from 5% to 6% (P<0.001). Patients diagnosed after 2014 were more frequently treated at Academic Cancer Programs (60% vs. 57%, P<0.001). Government-sponsored insurance increased from 57% to 65%, whereas uninsured patients rate declined from 2.4% to 1.6% (P<0.001). Patients diagnosed after 2014 more frequently presented with stage III (16% vs. 13%) and stage IV disease (63% vs. 60%), while stage I disease decreased from 8% to 7% (all P<0.001). Significant differences were also observed in household income, educational attainment, and urban residence (all P<0.001), whereas Charlson-Deyo comorbidity scores remained comparable between eras (P=0.20).

OS improved substantially over time irrespective of Medicaid expansion status. In expansion states, estimated 2-, 5-, and 10-year OS improved from 71%, 52%, and 34% before expansion to 73%, 56%, and 39% after expansion. In non-expansion states, corresponding OS improved from 69%, 51%, and 34% to 73%, 56%, and 37%, respectively. Adjusted Kaplan-Meier analyses demonstrated no significant differences in OS between expansion and non-expansion states before (log-rank P=0.32) or after (log-rank P=0.38) ACA implementation. DiD analysis similarly demonstrated no independent association between Medicaid expansion and long-term OS, indicating that survival improvements during the contemporary era were comparable irrespective of expansion status.  

Conclusions

OS among patients with MCL improved substantially during the ACA era. However, Medicaid expansion was not independently associated with improved long-term survival after accounting for nationwide temporal trends. These findings suggest that advances in MCL management including modern immunochemotherapy, targeted therapies, maintenance strategies, and supportive care rather than insurance expansion alone, were the primary drivers of improved survival during the contemporary treatment era.

Eleftheria Atalla, MD: No relevant conflicts of interest to declare.